Neuroscientific Biopharmaceuticals Ltd (ASX:NSB)

35.0¢

right-arrow Created with Sketch. -0.005 (-1.41%)
MCAP $50.21M
Last trade 15.10pm 01/12/2021 20mins delayed

Latest Announcements

22/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
18/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
11/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
11/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
11/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
02/11/2021NSBNeuroscientific Biopharmaceuticals Ltd
29/10/2021 Price SensitivePSNSBNeuroscientific Biopharmaceuticals Ltd
26/10/2021NSBNeuroscientific Biopharmaceuticals Ltd

Company Overview

NeuroScientific Biopharmaceuticals Ltd is an Australia-based company, which develops peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with unmet medical demand. The company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinBTM is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

NSB in the news

NeuroScientific Biopharmaceuticals (NSB) records no adverse events during its non-clinical studies of…
NeuroScientific Biopharmaceuticals (NSB) receives Advance and Overseas Finding by AusIndustry for the…
NeuroScientific Biopharmaceuticals (NSB) says new biomarker data highlights the potential for its…
NeuroScientific Biopharmaceuticals (NSB) opens green on the ASX after lab tests show…

Search Previous Announcements